Dissection of mechanisms that account for imidazoline-induced lowering of blood glucose in mice.

[1]  A. Luger,et al.  Mechanisms of antihyperglycaemic action of efaroxan in mice: time for reappraisal of α2A-adrenergic antagonism in the treatment of type 2 diabetes? , 2012, Diabetologia.

[2]  L. Carriquiry.  More Is Not Always Better , 2011, World Journal of Surgery.

[3]  M. Scheinin,et al.  α2-adrenoceptor regulation of blood glucose homeostasis. , 2011, Basic & clinical pharmacology & toxicology.

[4]  J. Henquin,et al.  Pharmacological stimulation and inhibition of insulin secretion in mouse islets lacking ATP‐sensitive K+ channels , 2010, British journal of pharmacology.

[5]  F. Gribble.  Alpha2A-adrenergic receptors and type 2 diabetes. , 2010, The New England journal of medicine.

[6]  L. Groop,et al.  Overexpression of Alpha2A-Adrenergic Receptors Contributes to Type 2 Diabetes , 2010, Science.

[7]  J. Wess.  More is not always better: alpha2A-adrenoceptor expression in type 2 diabetes. , 2010, Cell metabolism.

[8]  S. Liggett.  α2A-Adrenergic Receptors in the Genetics, Pathogenesis, and Treatment of Type 2 Diabetes , 2009, Science Translational Medicine.

[9]  K. Hatlapatka,et al.  Selective Enhancement of Nutrient-Induced Insulin Secretion by ATP-Sensitive K+ Channel-Blocking Imidazolines , 2009, Journal of Pharmacology and Experimental Therapeutics.

[10]  I. Rustenbeck,et al.  Effects of imidazoline compounds on cytoplasmic Ca2+ concentration and ATP-sensitive K+ channels in pancreatic B-cells. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[11]  I. Lundquist,et al.  Imidazoline‐induced amplification of glucose‐ and carbachol‐stimulated insulin release includes a marked suppression of islet nitric oxide generation in the mouse , 2009, Acta physiologica.

[12]  M. Scheinin,et al.  α2A‐Adrenoceptor antagonism increases insulin secretion and synergistically augments the insulinotropic effect of glibenclamide in mice , 2008, British journal of pharmacology.

[13]  P. Berggren,et al.  Arachidonic acid signaling is involved in the mechanism of imidazoline-induced KATP channel-independent stimulation of insulin secretion , 2007, Cellular and Molecular Life Sciences.

[14]  D. Friedman,et al.  Proteomic exploration of pancreatic islets in mice null for the alpha2A adrenergic receptor. , 2005, Journal of molecular endocrinology.

[15]  M. Scheinin,et al.  Altered glucose homeostasis in α2A-adrenoceptor knockout mice , 2004 .

[16]  A. Verma,et al.  More Is Not Always Better , 2003, Journal of cardiovascular electrophysiology.

[17]  P. Berggren,et al.  Two generations of insulinotropic imidazoline compounds. , 2002, Diabetes.

[18]  N. Morgan,et al.  Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues? , 2001, Current pharmaceutical design.

[19]  N. Morgan,et al.  Characterization of a KATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan. , 2001, Diabetes.

[20]  I. Rustenbeck,et al.  Imidazolines and the Pancreatic B‐Cell: Actions and Binding Sites , 1999, Annals of the New York Academy of Sciences.

[21]  C. A. Ramsden,et al.  Affinity isolation of imidazoline binding proteins from rat brain using 5‐amino‐efaroxan as a ligand , 1999, FEBS letters.

[22]  F. Ashcroft,et al.  Phentolamine block of KATP channels is mediated by Kir6.2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. M. Shepherd,et al.  Elevation of cytosolic calcium by imidazolines in mouse islets of Langerhans: implications for stimulus‐response coupling of insulin release , 1996, British journal of pharmacology.

[24]  O. Larsson,et al.  Imidazoline Compounds Stimulate Insulin Release by Inhibition of KATP Channels and Interaction With the Exocytotic Machinery , 1996, Diabetes.

[25]  S. Z. Langer,et al.  Involvement of alpha-2 adrenergic receptor subtypes in hyperglycemia. , 1990, The Journal of pharmacology and experimental therapeutics.

[26]  N. Morgan,et al.  Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels. , 1990, European journal of pharmacology.

[27]  A. Hasselblatt,et al.  An insulin-releasing property of imidazoline derivatives is not limited to compounds that block α-adrenoceptors , 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.

[28]  S. Efendić,et al.  Alpha-adrenoceptors and insulin release from pancreatic islets of normal and diabetic rats. , 1989, The American journal of physiology.

[29]  C. Östenson,et al.  Alpha 2-adrenoceptor blockade does not enhance glucose-induced insulin release in normal subjects or patients with noninsulin-dependent diabetes. , 1988, The Journal of clinical endocrinology and metabolism.

[30]  A. Hasselblatt,et al.  Phentolamine, a deceptive tool to investigate sympathetic nervous control of insulin release , 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.

[31]  J. Halter,et al.  A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus. , 1976, The Journal of clinical investigation.

[32]  K. Ratzmann,et al.  [Adrenergic modulation of basal insulin secretion in obesity]. , 1974, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete.

[33]  D. Porte,et al.  Adrenergic Modulation of Basal Insulin Secretion in Man , 1973, Diabetes.

[34]  M. Buse,et al.  Effect of α-adrenergic blockade on insulin secretion in man , 1970 .

[35]  T. Lackmann,et al.  Antagonism of the insulinotropic action of first generation imidazolines by openers of K(ATP) channels. , 2007, Biochemical pharmacology.

[36]  M. Scheinin,et al.  Altered glucose homeostasis in alpha2A-adrenoceptor knockout mice. , 2004, European journal of pharmacology.

[37]  Y. Kasuya,et al.  Involvement of alpha 2-adrenergic receptors in the vagal reflex-induced tracheal constriction. , 1990, Journal of pharmacobio-dynamics.